Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 34Lung Neoplasms 23Carcinoma, Non-Small-Cell Lung 18Neoplasms 15Uterine Cervical Neoplasms 9Esophageal Neoplasms 9Brain Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Solid Tumor 7Rectal Neoplasms 7Lymphoma 7Glioblastoma 7Carcinoma, Hepatocellular 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Neoplasm Metastasis 6Multiple Myeloma 6Melanoma 6Hodgkin Disease 6Colorectal Neoplasms 6Colonic Neoplasms 6Carcinoma, Renal Cell 6Breast Neoplasms, Male 6Stomach Neoplasms 5Sarcoma 5Neuroendocrine Tumors 5Lymphoma, Large B-Cell, Diffuse 5Carcinoma, Transitional Cell 5Thyroid Neoplasms 4Ovarian Neoplasms 4

Interventions

Cyclophosphamide 41Peripheral Blood Stem Cell Transplantation 40fludarabine phosphate 36Whole-Body Irradiation 27Mycophenolic Acid 27Tacrolimus 23Busulfan 23Cyclosporine 22Antilymphocyte Serum 20Etoposide 17Methotrexate 16Filgrastim 16Melphalan 14romidepsin 13Radiotherapy 13Flow Cytometry 12Methylprednisolone 10Brentuximab Vedotin 10Therapeutics 9Psychiatric Rehabilitation 9Lenalidomide 8pembrolizumab 7fludarabine 7Sirolimus 7Rituximab 7Bortezomib 7Bexarotene 7mogamulizumab 6Polymerase Chain Reaction 6Gemcitabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, T-Cell, Cutaneous × Fluorodeoxyglucose F18 × Clear all
NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Mayo Clinic

Phase 1 Terminated
17 enrolled
BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡